Northwestern University professor Hande Ozdinler is hoping to change how ALS is treated, saying the disease is too complex ...

Alterity presents positive phase II data for ATH434 at 2025 International Congress of Parkinson’s Disease and Movement Disorders. Alterity presents positive phase II data for ATH434 at 2025 ...

The sudden shift of Hyderabad Metro Rail (HMR) and Hyderabad Airport Metro Limited (HAML) Managing Director N.V.S. Reddy from his post — held since 2007 — marks the end of a long tenure that began ...

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing ...

I'm basically dumbstruck how come the Ford Motor Company thought it could dupe folks into thinking their 815-hp Ford Mustang ...

The next wave of high-efficiency DC-DC converters will reshape power delivery in applications ranging from DC microgrids to ...

BlueRock Therapeutics reports positive 36-month results from phase I trial of bemdaneprocel for treating Parkinson’s disease: Berlin, Germany Wednesday, October 8, 2025, 18:00 H ...

According to Kuntzman, “A phase is short-lived, that may pop up for a few days or a few weeks, and is usually tied to a developmental leap, big life change ... motor abilities—especially when it’s not ...

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically ...